To our best knowledge, the expression of ezrin in urothelial bladder cancer has only been described in two previous studies; one selected cohort of T1G3 tumours (n = 98) treated with non-maintenance BCG [7], and another unselected cohort (n = 104). Here, EZR is linked to neoplasm.